Full Text

Turn on search term navigation

© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

In Japan, inactivated influenza vaccines are used. We measured titers of antibodies to vaccine strains of three influenza types—influenza A (H1N1), influenza A (H3N2), and influenza B/Victoria—from the 2017/2018 to 2021/2022 seasons, but not for influenza A (H3N2) from the 2018/2019 season, using a single set of serum samples from 34 healthy volunteers, and assessed the consistency in antibody positivity between seasons. The antibody titers in the 2017/2018 season were used as a reference. The influenza A (H1N1) antibody titer in 2019/2020 did not differ significantly from that in the 2017/2018 season, but the titers varied in the two subsequent seasons. The influenza A (H3N2) antibody titers toward the 2019/2020, 2020/2021, and 2021/2022 seasonal viruses differed significantly from that in the 2017/2018 season. The influenza B/Victoria antibody titer toward the 2019/2020 seasonal antigen differed from that in the 2017/2018 season, and the antibody positivity was inconsistent between seasons; however, the antibody titer in the 2020/2021 season did not differ significantly from those in the prior two seasons, and the antibody positivity was consistent between seasons. Antibody titers and their consistency can be used to evaluate cross-immunity of antibodies.

Details

Title
Comparison of the Hemagglutination Inhibition Titers against Influenza Vaccine Strains in Japan from the 2017/2018 to 2021/2022 Seasons Using a Single Set of Serum Samples
Author
Otani, Naruhito 1 ; Nakajima, Kazuhiko 2 ; Ishikawa, Kaori 2 ; Ichiki, Kaoru 2 ; Yoda, Yoshiko 1 ; Ueda, Takashi 2   VIAFID ORCID Logo  ; Takesue, Yoshio 2 ; Yamamoto, Takuma 3 ; Tanimura, Susumu 4   VIAFID ORCID Logo  ; Shima, Masayuki 1   VIAFID ORCID Logo  ; Okuno, Toshiomi 5 

 Department of Public Health, Hyogo Medical University, Nishinomiya 663-8501, Japan; [email protected] (Y.Y.); [email protected] (M.S.) 
 Department of Infection Control and Prevention, Hyogo Medical University, Nishinomiya 663-8501, Japan; [email protected] (K.N.); [email protected] (K.I.); [email protected] (K.I.); [email protected] (T.U.); [email protected] (Y.T.) 
 Department of Legal Medicine, Hyogo Medical University, Nishinomiya 663-8501, Japan; [email protected] 
 Department of Public Health Nursing, Mie University Graduate School of Medicine, Tsu 514-0001, Japan; [email protected] 
 Department of Microbiology, Hyogo Medical University, Nishinomiya 663-8501, Japan; [email protected] 
First page
1455
Publication year
2022
Publication date
2022
Publisher
MDPI AG
e-ISSN
19994915
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2694037785
Copyright
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.